“We are excited that Dyne’s first clinical data in two programs have demonstrated proof-of-concept and validated the promise of the FORCE™ platform in developing targeted therapeutics for rare muscle diseases. In addition to the opportunity with our co-lead programs, this clinical validation reinforces the potential of FORCE to deliver for patients in other areas, including building a global DMD franchise, addressing FSHD and exploring diseases involving the CNS,” said Joshua Brumm, Dyne’s president and chief executive officer. “The safety profiles for both DYNE-101 and DYNE-251 have supported dose escalation to a combined 10 cohorts and the administration of nearly 600 doses across both the ACHIEVE and DELIVER trials. This positions us to optimize dose and dose regimen in both trials with the goal of initiating registrational cohorts as we end 2024. We anticipate reporting data for multiple, higher dose cohorts from both trials in the second half of 2024, while continuing to pursue expedited regulatory pathways and working to help address the urgent need for therapeutics for people living with DM1 and Duchenne.”
SV thanks for the 2 previous posts. DT are only at “proof of concept stage” Their results are due end of 2024 PER should have the DMD results done and dusted by then Ok DT has a Market Cap of $1.3 billion US. Per less than $50 million So heres the thing.. Once PER results come out that we have met our end points: we should have a MC over $1.3 billion US Thats $2 Aud .. 48 c options triggered: Money in the bank .. no need to rush Looking for a Partner. Now SV your post earlier where you had a go at CG Was it justified When 99% of shareholders including Platinum and AeF were happy that it was a just reward… Moses and Diamond did not have the expertise to take Atl1102 any further. Simple as that..
PER Price at posting:
5.9¢ Sentiment: Buy Disclosure: Held
